Actively Recruiting
Study of the Immunological Pathophysiological Mechanisms Associated With Acute Respiratory Distress Syndrome
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-05-14
50
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
About 10% of patients admitted to the ICU suffer from ARDS, with a mortality rate of around 35-45%. The lack of therapeutic innovation in ARDS can be partly explained by the heterogeneity of patients included under this definition. A better understanding of the pathophysiological mechanisms underlying the different patient phenotypes is essential to develop new therapeutic strategies. Objectives: To characterize the inflammatory profile of patients with ARDS using circulating biomarkers and single-cell RNA sequencing of pulmonary immune cells. The investigators hypothesize that there is a correlation between the profile of serum biomarkers (inflammatory sub-phenotypes), the transcriptome of pulmonary immune cells. Briefly the experimental scheme is as follow: * Population: patients with ARDS under invasive mechanical ventilation in the ICU. * Intervention: 1. Determination of the inflammatory subphenotype on circulatory inflammatory biomarkers. 2. Characterization of inflammation by single cell RNA sequencing on lung immune cells collected on broncho-alveolar fluid.
CONDITIONS
Official Title
Study of the Immunological Pathophysiological Mechanisms Associated With Acute Respiratory Distress Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- ARDS risk factors including bacterial or viral pneumonia, extrapulmonary infection, major trauma, transfusion, inhalation injury, or shock
- Pulmonary edema not caused by heart problems or fluid overload
- Respiratory symptoms started less than 7 days ago
- Bilateral lung involvement seen on chest X-ray, CT scan, or ultrasound
- PaO2/FiO2 ratio less than or equal to 300 with PEEP of at least 5 cmH2O
You will not qualify if you...
- Intubated for ARDS for more than 48 hours
- Contraindications to bronchoscopy such as effective anticoagulation, dual antiplatelet therapy, or low platelet count below 50 G/L
- Pre-existing immunodeficiency including active or recent solid tumor or blood cancer, systemic disease, organ or bone marrow transplant, or HIV with low CD4 count
- Poor prognosis after cardiac arrest (high NSE, malignant EEG, brain ischemia, loss of reflexes)
- Under 18 years old
- Under legal guardianship, curatorship, or deprived of liberty
- Pregnant
- Without social security coverage
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Lariboisière
Paris, France, 75010
Actively Recruiting
Research Team
P
Pierre-Louis BLOT, MD
CONTACT
B
Benjamin Chousterman, MD PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here